Angelalign Technology to Appeal Chinese Court Ruling Without Customer Impact

Angelalign Technology's Appeal Update

Angelalign Technology Inc. has announced that it will be appealing a recent ruling made by the Intermediate People's Court of Jinan, China, concerning its premolar extraction solution. The court mandated that Angel's Chinese subsidiaries cease using their biomechanical simulation system, masterForce, and their digital diagnosis and construction system, ATreat, for solutions related to premolar extraction with the A7 and A7 Speed systems. This preliminary ruling is specific to China and is not yet in effect, meaning it will not affect Angel's customers or patients in any way.

CEO Fox Hu articulated his confidence regarding the appeal, stating, “The decision only applies to China, and there are no immediate impacts on our customers, even within China.” Angelalign is firm in their belief that their A7 Premolar Extraction Solution does not infringe on any valid patents and has won numerous patent disputes in different jurisdictions worldwide.

The implications of this case arise from a larger legal conflict with Align Technology, Inc., which claims that Angelalign has infringed on its patents. The Jinan court's decision would only be implemented if Angel's appeal fails, in which case it is anticipated that an ongoing appeal from Angel will continue.

Context of the Case

In this dispute, Angelalign maintains a strong stance regarding its commitment to fair competition within the orthodontics and scanner markets. Recently, on May 12, 2026, the Unified Patent Court in Düsseldorf, Germany, rejected the request for a preliminary injunction that would have compelled Angel to stop using the A7 Premolar Extraction Solution, giving Angel a favorable ruling that solidifies their position in Europe. The European patent in question shares familial ties with the Chinese patent at hand, suggesting that the legal arguments may have shared evidence or context.

Furthermore, on June 26, 2026, two other patent infringement claims initiated by the same plaintiff against Angel were dismissed by the Intermediate People's Court in Zhengzhou, showcasing an ongoing trend of favorable outcomes for Angel in their legal battles. The plaintiff in this case has filed appeals against those rulings.

Over its 20-year history, Angelalign has been a pioneer in dental technology, with over 2 million patients globally benefiting from its innovative solutions. Renowned orthodontists often regard Angelalign as a leader in handling complex orthodontic cases, with established competitors also taking cues from Angel's offerings, including the angelButton™ and A6 Mandibular Advancement systems.

Future Outlook

With a market capitalization of $2 billion and substantial profitability, Angelalign possesses a solid financial foundation to continue as a dependable partner for orthodontists seeking exceptional clinical outcomes. With over 60 countries and regions now served by its products, the company has also expanded into the North American market and has recently established a new 52,000 square-foot production facility in the USA, marking a significant expansion in operational capacity.

This ongoing legal dispute highlights the complex nature of patent law in the rapidly evolving dental technology market. As Angelalign continues its fight in the courts, they remain committed to upholding their intellectual property rights while striving to deliver innovative solutions to orthodontists and their patients worldwide.

For more information about Angelalign Technology Inc. and their ongoing legal proceedings, visit their official website here.